It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the party responsible for enrolling patients, just follow the hyperlink.** To learn more, visit “Information About Clinical Trials” at braintumor.org.
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors
- A phase I/II trial to evaluate the best dose, side effects, and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors that have come back (relapsed) or do not respond to treatment (refractory)
- A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
- This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population.
- AZD1390 in Recurrent Grade IV Glioma Patients
- A phase 0/Ib study that will enroll at least 14 participants with recurrent WHO Grade IV glioma requiring re-radiation. Patients with tumors demonstrating a positive response in the phase 0 component of the study will graduate to an expansion phase that combines therapeutic dosing of AZD1390 plus standard-of-care fractionated radiotherapy (RT).
- PARP Inhibition for Gliomas (PI-4G or π4g)
- A phase II study is to determine what effects the drug niraparib has on patients with recurrent brain cancer.
- Tumor Treating Fields for the Treatment of Brainstem Gliomas
- A clinical trial to evaluate the safety and side effects of tumor treating fields in patients with gliomas located in the brainstem.
- Safety and Tolerability of fb-PMT in Recurrent Glioblastoma
- This phase I study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent GBM.
- ASP8374 + Cemiplimab in Recurrent Glioma
- This phase I study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma.
- Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)
- The purpose of this early phase I study is to determine if using avatrombopag in patients with thrombocytopenia due to temozolomide treatment can safely improve a patient’s platelet count and allow the patient to complete the temozolomide treatment course as planned.
- Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- This phase II study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
- Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
- This is a phase II study of pemigatinib in participants with recurrent GBM or other primary CNS tumors with an activating FGFR1-3 mutation or fusion/rearrangement.
- HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
- This is a phase I study to evaluate the safety of a type of immunotherapy called HER2 CAR T cells. In addition to looking for side effects, researchers will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (recurrent) or has not responded well to treatment (progressive) in children.
- Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
- This clinical study evaluates if a technique/technology called sonobiopsy can enhance a clinician’s insight into the molecular features of a brain tumor to tailor treatment approaches and optimize outcomes.
- Chlorpromazine and Standard of Care in Glioblastoma
- This is a phase I study investigating the repurposing of the drug chlorpromazine, combined with temozolomide and radiation in the treatment of newly diagnosed GBM.
- A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
- This is a phase I pilot study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral injection of C5252 in patients with recurrent or progressive GBM.
- Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
- This is a phase I trial to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed GBM.
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- A phase II study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma and ependymoma.
- CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent Glioblastoma With IDH-1 Wild Type (CYNK001GBM02)
- A phase I/IIa trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin-2 in adults with recurrent, resection-eligible IDH1 wild-type GBM.
- Sacituzumab Govitecan in Recurrent Glioblastoma
- This is a single-arm phase II study to determine if the treatment Sacituzumab Govitecan can improve progression-free survival for GBM patients.
- Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma (PNOC027)
- This is a pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC) for relapsed medulloblastoma patients (children and adults), who will receive an individualized treatment recommendation including up to four FDA-approved drugs based on the results of real-time biomarker testing.
- Study of BDTX-1535, in Participants With Glioblastoma
- This is a pilot study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM harboring EGFR alterations and who have disease progression following standard of care.
- A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
- This is a phase I/II trial of avapritinib in patients aged 2-18 years with relapsed/refractory solid tumors with mutations to KIT or PDGFRA, or gliomas with the H3K27M mutation, and no available alternative treatment options.
- MRI in High-Grade Glioma Patients Undergoing Chemoradiation
- The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests.
- Cabozantinib for Patients With Recurrent or Progressive Meningioma
- A phase II study of cabozantinib for patients with recurrent or progressive meningioma.
- Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas (POPLAR-NF2)
- This is a phase II/III trial to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
- Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- This trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
*For a comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder at trials.braintumor.org, where you can search for potential opportunities for enrollment based on criteria specific to you.
**For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing patientnavigator@braintumor.org. Learn more here.
